Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Raised by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,590 shares of the biopharmaceutical company’s stock after purchasing an additional 7,090 shares during the period. E. Ohman J or Asset Management AB’s holdings in Gilead Sciences were worth $5,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Avior Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 1.2% in the third quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Southland Equity Partners LLC raised its position in Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 110 shares during the period. Concord Asset Management LLC VA lifted its stake in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 111 shares in the last quarter. Berkshire Bank boosted its position in Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 111 shares during the period. Finally, TFB Advisors LLC grew its stake in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 116 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 598,414 shares of company stock valued at $55,953,200 in the last 90 days. 0.29% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research report on Monday. Robert W. Baird increased their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Bank of America reissued a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Oppenheimer boosted their price target on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Stock Up 1.2 %

GILD stock opened at $98.38 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $99.45. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a market cap of $122.61 billion, a PE ratio of 1,093.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The business’s 50-day simple moving average is $92.42 and its 200 day simple moving average is $85.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.